oxybutynin hydrochloride: clinical use

Prescribing considerations

• Confirm that frequency or nocturia is not secondary to cardiac or renal failure and assess for urinary outflow or gastrointestinal obstruction.
• Consider cumulative anticholinergic burden, especially in frail older people and those with cognitive impairment, Parkinson’s disease or autonomic neuropathy.
• Use caution with hepatic or renal impairment, severe gastrointestinal dysmotility, reflux disease, tachyarrhythmia, cardiovascular disease, hyperthyroidism and prostatic enlargement.
• Children may be more susceptible to central nervous system and psychiatric adverse effects.
• Intravesical treatment requires neuro-urology supervision, catheter competence and attention to urinary tract infection.

Contraindications and cautions

• Product-specific contraindications commonly include hypersensitivity, myasthenia gravis, narrow-angle glaucoma, urinary retention or significant bladder outflow obstruction, gastrointestinal obstruction or atony, severe ulcerative colitis and toxic megacolon.
• Some selected oral products additionally list porphyria and urinary frequency or nocturia caused by cardiac or renal failure.
• The selected intravesical product additionally contraindicates concomitant oxygen therapy; always check the exact formulation’s SmPC.

Monitoring

• Assess symptom response and continuing need for treatment.
• Monitor dry mouth and oral health, constipation, urinary retention, blurred vision and reduced sweating or heat intolerance.
• Monitor for confusion, hallucinations, agitation, sleep disturbance or other cognitive and psychiatric effects, particularly after initiation or treatment changes and in older people or children.
• For intravesical treatment, monitor urodynamic response and assess for urinary tract infection.

Clinical pharmacology

Oxybutynin is a competitive muscarinic receptor antagonist with direct smooth-muscle antispasmodic activity. Oral oxybutynin undergoes extensive CYP3A4-mediated first-pass metabolism to an active N-desethyl metabolite. Prolonged-release tablets provide more sustained delivery, while intravesical administration reduces first-pass metabolism but still produces variable systemic absorption.

Formulation and product differences

• Standard tablets and oral solutions are immediate-release oral formulations.
• Prolonged-release tablets must remain intact and may leave an empty membrane in the stool.
• Oral-solution excipients and measuring devices differ between products; check the specific SmPC and leaflet where sugar intolerance or excipient exposure matters.
• Intravesical solution is administered through a catheter for a restricted specialist indication and is not interchangeable with oral products.

Modified-release tablet

Route: Oral

Strengths: 5 mg, 10 mg

Oral solution

Route: Oral

Strengths: 2.5 mg/5 mL, 5 mg/5 mL